| Dr Penner T Schraudenbach, MD | |
|
506 Graham Dr Ste 150, Tomball, TX 77375-3346 | |
| (281) 351-5174 | |
| (281) 351-5172 |
| Full Name | Dr Penner T Schraudenbach |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 20 Years |
| Location | 506 Graham Dr Ste 150, Tomball, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477738409 | NPI | - | NPPES |
| P01366412 | Other | TX | RAILROAD MEDICARE |
| TXB120824 | Other | TX | MEDICARE HARRIS |
| 338511401 | Medicaid | TX | |
| 1700816428 | Other | TX | NPI |
| 338511402 | Medicaid | TX | |
| TXB120811 | Other | TX | MEDICARE MONTGOMERY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | N1132 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Houston Methodist Willowbrook Hospital | Houston, TX | Hospital |
| St Luke's Hospital At The Vintage | Houston, TX | Hospital |
| Houston Methodist The Woodlands Hospital | The woodlands, TX | Hospital |
| Hca Houston Healthcare Tomball | Tomball, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Texas Oncology Pa | 5395658934 | 855 |
News Archive
"The results of this study are consistent with an American study which found that outdoor sport was protective, however our study shows that the crucial feature is being outdoors irrespective of the activity you are doing."
Octapharma AG, one of the largest global manufacturers of human proteins, today announced the enrolment of the first two patients in its GAM-27 Phase II/III clinical trial for the treatment of relapsing multiple sclerosis. Through intravenous administration of immunoglobulin (Octagam 5%), the study seeks to support the overall clinical benefit of a lower annualised relapse rate in patients where first-line treatment is not suitable.
Rigel Pharmaceuticals Inc. today announced that it has initiated a Phase 2 clinical trial to evaluate fostamatinib, its oral SYK inhibitor, as a potential treatment for autoimmune hemolytic anemia (AIHA).
La Jolla Pharmaceutical Company (Nasdaq: LJPC) announced today that it has received a notice from the Nasdaq Stock Market indicating that the Company is not in compliance with Nasdaq Marketplace Rule 5550(a)(2) (the "Minimum Bid Price Rule") because, for the last 30 consecutive days, the bid price for the Company's common stock has closed below the minimum level of $1.00 per share.
› Verified 3 days ago
| Entity Name | Texas Oncology Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811944101 PECOS PAC ID: 5395658934 Enrollment ID: O20031124000323 |
News Archive
"The results of this study are consistent with an American study which found that outdoor sport was protective, however our study shows that the crucial feature is being outdoors irrespective of the activity you are doing."
Octapharma AG, one of the largest global manufacturers of human proteins, today announced the enrolment of the first two patients in its GAM-27 Phase II/III clinical trial for the treatment of relapsing multiple sclerosis. Through intravenous administration of immunoglobulin (Octagam 5%), the study seeks to support the overall clinical benefit of a lower annualised relapse rate in patients where first-line treatment is not suitable.
Rigel Pharmaceuticals Inc. today announced that it has initiated a Phase 2 clinical trial to evaluate fostamatinib, its oral SYK inhibitor, as a potential treatment for autoimmune hemolytic anemia (AIHA).
La Jolla Pharmaceutical Company (Nasdaq: LJPC) announced today that it has received a notice from the Nasdaq Stock Market indicating that the Company is not in compliance with Nasdaq Marketplace Rule 5550(a)(2) (the "Minimum Bid Price Rule") because, for the last 30 consecutive days, the bid price for the Company's common stock has closed below the minimum level of $1.00 per share.
› Verified 3 days ago
| Entity Name | Texienne Oncology Centers, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700017449 PECOS PAC ID: 7012054281 Enrollment ID: O20091020000492 |
News Archive
"The results of this study are consistent with an American study which found that outdoor sport was protective, however our study shows that the crucial feature is being outdoors irrespective of the activity you are doing."
Octapharma AG, one of the largest global manufacturers of human proteins, today announced the enrolment of the first two patients in its GAM-27 Phase II/III clinical trial for the treatment of relapsing multiple sclerosis. Through intravenous administration of immunoglobulin (Octagam 5%), the study seeks to support the overall clinical benefit of a lower annualised relapse rate in patients where first-line treatment is not suitable.
Rigel Pharmaceuticals Inc. today announced that it has initiated a Phase 2 clinical trial to evaluate fostamatinib, its oral SYK inhibitor, as a potential treatment for autoimmune hemolytic anemia (AIHA).
La Jolla Pharmaceutical Company (Nasdaq: LJPC) announced today that it has received a notice from the Nasdaq Stock Market indicating that the Company is not in compliance with Nasdaq Marketplace Rule 5550(a)(2) (the "Minimum Bid Price Rule") because, for the last 30 consecutive days, the bid price for the Company's common stock has closed below the minimum level of $1.00 per share.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Penner T Schraudenbach, MD Po Box 911230, Dallas, TX 75391-1230 Ph: (972) 997-8000 | Dr Penner T Schraudenbach, MD 506 Graham Dr Ste 150, Tomball, TX 77375-3346 Ph: (281) 351-5174 |
News Archive
"The results of this study are consistent with an American study which found that outdoor sport was protective, however our study shows that the crucial feature is being outdoors irrespective of the activity you are doing."
Octapharma AG, one of the largest global manufacturers of human proteins, today announced the enrolment of the first two patients in its GAM-27 Phase II/III clinical trial for the treatment of relapsing multiple sclerosis. Through intravenous administration of immunoglobulin (Octagam 5%), the study seeks to support the overall clinical benefit of a lower annualised relapse rate in patients where first-line treatment is not suitable.
Rigel Pharmaceuticals Inc. today announced that it has initiated a Phase 2 clinical trial to evaluate fostamatinib, its oral SYK inhibitor, as a potential treatment for autoimmune hemolytic anemia (AIHA).
La Jolla Pharmaceutical Company (Nasdaq: LJPC) announced today that it has received a notice from the Nasdaq Stock Market indicating that the Company is not in compliance with Nasdaq Marketplace Rule 5550(a)(2) (the "Minimum Bid Price Rule") because, for the last 30 consecutive days, the bid price for the Company's common stock has closed below the minimum level of $1.00 per share.
› Verified 3 days ago
Dr. Steven Wayne Sukin, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 506 Graham Dr, Ste 150, Tomball, TX 77375 Phone: 281-351-5174 Fax: 281-351-5172 | |
Matthew M Hogan, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 919 Graham Dr, Tomball, TX 77375 Phone: 281-516-6530 Fax: 281-290-9824 | |
Liliana Woo, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 919 Graham Dr, Tomball, TX 77375 Phone: 281-516-6530 Fax: 281-290-9824 | |
Dr. Miguel Angel Mercado, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 506 Graham Dr Ste 150, Tomball, TX 77375 Phone: 281-351-5174 Fax: 281-381-5172 | |
Jerry D Rouse, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 13414 Medical Complex Dr, Ste. 13, Tomball, TX 77375 Phone: 281-351-8229 | |
Dr. Clyde Leland Corey, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 919 Graham Dr, Tomball, TX 77375 Phone: 281-516-6530 Fax: 281-290-9824 |